Senores Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 27 Jul 2026

Company page: Senores Pharmaceuticals share price, financials & guidance record

Senores Pharmaceuticals Limited reported a strong Q1 FY27, with consolidated revenue up 36% to INR180 crores and PAT growing 56% to INR31 crores, driven by robust performance in regulated markets. EBITDA margins expanded significantly to 30%. The company is focused on expanding its ANDA portfolio and commercialization, with a long-term revenue target of INR2,500-3,000 crores in 3-4 years, while strategically reallocating IPO proceeds from sterile injectables to oral solids for quicker revenue generation.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 30.4%, net profit up 42.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	101	103	114	138	162 +60%	171 +66%	175 +54%	180 +30%
Expenses	77	77	95	104	112	121	128	126
EBITDA	23	26	19	34	50 +117%	50 +92%	47 +147%	54 +59%
Margin	23%	25%	17%	25%	31%	29%	27%	30%
Other income	2	5	12	3	5	7	18	3
Interest	5	6	5	5	6	5	8	7
Depreciation	4	4	5	6	8	8	9	10
Profit before tax	16	20	21	26	41 +156%	45 +125%	47 +124%	39 +50%
Tax rate	18%	20%	13%	20%	26%	25%	23%	23%
Net profit	13	16	18	21	30 +131%	34 +113%	37 +106%	30 +43%
EPS	3.86	3.73	3.87	4.28	7.03	6.87	6.86	6.67

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls